TBC1D9

Summary

TBC1D9 (TBC1 domain family member 9, HGNC:21710) is a protein-coding gene on chromosome 4q31.21, encoding TBC1 domain family member 9 (Q6ZT07). May act as a GTPase-activating protein for Rab family protein(s).

Predicted to enable GTPase activator activity.

Source: NCBI Gene 23158 — RefSeq curated summary.

At a glance

• GWAS associations: 5
• Clinical variants (ClinVar): 151 total
• MANE Select transcript: NM_015130

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:21710
Approved symbol	TBC1D9
Name	TBC1 domain family member 9
Location	4q31.21
Locus type	gene with protein product
Status	Approved
Aliases	KIAA0882, MDR1, GRAMD9
Ensembl gene	ENSG00000109436
Ensembl biotype	protein_coding
OMIM	618035
Entrez	23158

Gene structure

Transcript identifiers

Ensembl transcripts: 6 — 4 protein_coding, 2 retained_intron

ENST00000442267, ENST00000502786, ENST00000514787, ENST00000855917, ENST00000970329, ENST00000970330

RefSeq mRNA: 1 — MANE Select: NM_015130 NM_015130

CCDS: CCDS47136

Canonical transcript exons

ENST00000442267 — 21 exons

Exon	Start	End
ENSE00000800757	140624116	140624219
ENSE00000800760	140624314	140624388
ENSE00000800761	140627441	140627527
ENSE00000800773	140669634	140669804
ENSE00000800774	140670720	140670926
ENSE00000927398	140657097	140657226
ENSE00000927405	140668917	140669067
ENSE00001139031	140628300	140628365
ENSE00001139065	140657527	140657812
ENSE00001191357	140678942	140679203
ENSE00001191363	140679615	140679843
ENSE00001191571	140686344	140686462
ENSE00001747040	140620782	140622917
ENSE00002040929	140755916	140756385
ENSE00002495638	140659588	140659705
ENSE00002503945	140661893	140662107
ENSE00002515804	140701504	140701614
ENSE00003652647	140676894	140677101
ENSE00003988708	140633948	140634188
ENSE00003988722	140639330	140639428
ENSE00003988734	140639086	140639154

Expression profiles

Bgee: expression breadth ubiquitous, 287 present calls, max score 98.10.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 16.8355 / max 140.9170, expressed in 1651 samples.

FANTOM5 promoters (8 alternative TSS)

Promoter ID	TPM avg	Samples expressed
54134	7.1998	1568
54140	6.7475	1289
54139	1.0721	433
54138	0.5209	301
54136	0.4362	224
54137	0.3066	157
54135	0.3011	154
54133	0.2512	114

Top tissues by expression

293 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
mammary duct	UBERON:0001765	98.10	gold quality
choroid plexus epithelium	UBERON:0003911	97.88	gold quality
epithelium of mammary gland	UBERON:0003244	97.68	gold quality
palpebral conjunctiva	UBERON:0001812	97.02	gold quality
lateral nuclear group of thalamus	UBERON:0002736	96.02	gold quality
seminal vesicle	UBERON:0000998	95.43	gold quality
thoracic mammary gland	UBERON:0005200	95.17	gold quality
mammary gland	UBERON:0001911	95.12	gold quality
visceral pleura	UBERON:0002401	95.04	gold quality
pleura	UBERON:0000977	94.92	gold quality
dorsal root ganglion	UBERON:0000044	94.87	gold quality
parietal pleura	UBERON:0002400	94.85	gold quality
pons	UBERON:0000988	94.48	gold quality
trigeminal ganglion	UBERON:0001675	94.17	gold quality
substantia nigra pars compacta	UBERON:0001965	94.00	gold quality
cerebellar vermis	UBERON:0004720	93.98	gold quality
pigmented layer of retina	UBERON:0001782	93.97	gold quality
endothelial cell	CL:0000115	93.80	gold quality
germinal epithelium of ovary	UBERON:0001304	93.72	gold quality
corpus epididymis	UBERON:0004359	93.61	gold quality
renal medulla	UBERON:0000362	93.52	gold quality
postcentral gyrus	UBERON:0002581	92.96	gold quality
superior vestibular nucleus	UBERON:0007227	92.88	gold quality
epithelium of nasopharynx	UBERON:0001951	92.84	gold quality
parietal lobe	UBERON:0001872	92.63	gold quality
Brodmann (1909) area 23	UBERON:0013554	92.59	gold quality
substantia nigra pars reticulata	UBERON:0001966	92.41	gold quality
bronchial epithelial cell	CL:0002328	92.32	gold quality
superior frontal gyrus	UBERON:0002661	92.08	gold quality
Brodmann (1909) area 46	UBERON:0006483	92.00	gold quality

Single-cell (SCXA)

Detected in 4 experiment(s), a significant marker in 4.

Experiment	Marker?	Max mean expression
E-GEOD-131882	yes	1009.46
E-CURD-119	yes	46.72
E-HCAD-10	yes	19.53
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

134 targeting TBC1D9, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-340-5P	100.00	72.50	4437
HSA-MIR-5692B	100.00	71.32	2622
HSA-MIR-5692C	100.00	71.32	2622
HSA-MIR-4262	100.00	73.26	3931
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-4534	99.99	66.58	1907
HSA-MIR-181A-5P	99.99	72.96	2995
HSA-MIR-181B-5P	99.99	72.97	2996
HSA-MIR-181C-5P	99.99	72.95	2996
HSA-MIR-181D-5P	99.99	73.04	2997
HSA-MIR-548P	99.98	72.25	3784
HSA-MIR-5696	99.98	72.36	4487
HSA-MIR-568	99.98	69.86	2084
HSA-MIR-4775	99.98	75.00	6394
HSA-MIR-607	99.97	73.62	5593
HSA-MIR-6888-3P	99.97	65.95	1170
HSA-MIR-570-3P	99.96	72.41	4910
HSA-MIR-590-3P	99.96	74.34	6478
HSA-MIR-1468-3P	99.96	72.74	3797
HSA-MIR-23A-3P	99.95	74.24	3163
HSA-MIR-23B-3P	99.95	74.24	3163
HSA-MIR-23C	99.95	73.92	3192
HSA-MIR-101-3P	99.94	75.03	2230
HSA-MIR-335-3P	99.93	73.36	4958
HSA-MIR-515-5P	99.92	69.82	2343
HSA-MIR-519E-5P	99.92	69.62	2358
HSA-MIR-497-5P	99.92	71.83	2674
HSA-MIR-10527-5P	99.91	72.28	3754
HSA-MIR-589-3P	99.91	69.62	2088

Literature-anchored findings (GeneRIF, showing 5)

• Plasma levels of atazanavir were significantly higher in patients with MDR1 genotype CC than in those with CT or TT, and bilirubin levels correlated with atazanavir concentrations. (PMID:16355344)
• CD34+ leukemic subpopulation predominantly displays lower spontaneous apoptosis and has higher expression levels of MDR19TBC1 domain family member 9 (with GRAM domain) ) genes than CD34- cells in childhood AML (PMID:18228020)
• The MDR1 gene CT/TT genotype of C3435T was significantly associated with a shorter progression-free survival (PFS) and overall survival (OS). (PMID:22296392)
• This study concluded that diindolylmethane induces pregnane X receptor -regulated CYP3A4 and MDR1 gene expression. (PMID:25542144)
• TBC1D9 controls TBK1 activation during xenophagy and mitophagy through Ca(2+)-dependent ubiquitin-recognition.TBC1D9 is involved in TBK1 phosphorylation. (PMID:32034138)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	tbc1d9	ENSDARG00000059900
mus_musculus	Tbc1d9	ENSMUSG00000031709
rattus_norvegicus	Tbc1d9	ENSRNOG00000003496

Paralogs (45): RABGAP1 (ENSG00000011454), TBC1D22A (ENSG00000054611), TBC1D22B (ENSG00000065491), TBC1D1 (ENSG00000065882), EVI5 (ENSG00000067208), TBC1D25 (ENSG00000068354), TBC1D2 (ENSG00000095383), TBC1D10A (ENSG00000099992), SGSM3 (ENSG00000100359), TBC1D17 (ENSG00000104946), TBC1D13 (ENSG00000107021), TBC1D12 (ENSG00000108239), TBC1D30 (ENSG00000111490), TBC1D15 (ENSG00000121749), TBC1D5 (ENSG00000131374), TBC1D14 (ENSG00000132405), TBC1D8B (ENSG00000133138), TBC1D4 (ENSG00000136111), GRTP1 (ENSG00000139835), SGSM2 (ENSG00000141258), EVI5L (ENSG00000142459), TBCK (ENSG00000145348), USP6NL (ENSG00000148429), RABGAP1L (ENSG00000152061), SGSM1 (ENSG00000167037), TBC1D21 (ENSG00000167139), TBC1D2B (ENSG00000167202), TBC1D16 (ENSG00000167291), TBC1D10B (ENSG00000169221), TBC1D10C (ENSG00000175463), TBC1D28 (ENSG00000189375), TBC1D9B (ENSG00000197226), TBC1D8 (ENSG00000204634), TBC1D26 (ENSG00000214946), TBC1D3G (ENSG00000260287), TBC1D3K (ENSG00000273513), TBC1D3H (ENSG00000274226), TBC1D3D (ENSG00000274419), TBC1D3L (ENSG00000274512), TBC1D3 (ENSG00000274611)

Protein

Protein identifiers

TBC1 domain family member 9 — Q6ZT07 (reviewed: Q6ZT07)

Alternative names: TBC1 domain family member 9A

All UniProt accessions (1): Q6ZT07

UniProt curated annotations — full annotation on UniProt →

Function. May act as a GTPase-activating protein for Rab family protein(s).

Domain organisation. The arginine and glutamine fingers are critical for the GTPase-activating mechanism, they pull out Rab’s ‘switch 2’ glutamine and insert in Rab’s active site.

RefSeq proteins (1): NP_055945* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000195	Rab-GAP-TBC_dom	Domain
IPR002048	EF_hand_dom	Domain
IPR004182	GRAM	Domain
IPR011992	EF-hand-dom_pair	Homologous_superfamily
IPR011993	PH-like_dom_sf	Homologous_superfamily
IPR035969	Rab-GAP_TBC_sf	Homologous_superfamily
IPR036014	TCB1D9/TCB1D9B_PH-GRAM1	Domain
IPR036017	TCB1D9/TCB1D9B_PH-GRAM2	Domain

Pfam: PF00566, PF02893

UniProt features (14 total): domain 4, region of interest 3, site 2, sequence variant 2, chain 1, sequence conflict 1, compositionally biased region 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q6ZT07-F1	73.57	0.37

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (2): 601 (glutamine finger); 562 (arginine finger)

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 254 (showing top): GSE45365_CD8A_DC_VS_CD11B_DC_IFNAR_KO_MCMV_INFECTION_DN, KOBAYASHI_EGFR_SIGNALING_24HR_UP, MODULE_255, TGCACTT_MIR519C_MIR519B_MIR519A, MODULE_45, GOZGIT_ESR1_TARGETS_DN, MODULE_317, CROONQUIST_NRAS_SIGNALING_UP, RODWELL_AGING_KIDNEY_NO_BLOOD_DN, MODULE_66, DAVICIONI_RHABDOMYOSARCOMA_PAX_FOXO1_FUSION_UP, CREIGHTON_ENDOCRINE_THERAPY_RESISTANCE_1, LI_WILMS_TUMOR_VS_FETAL_KIDNEY_1_UP, WANG_LMO4_TARGETS_DN, SMID_BREAST_CANCER_LUMINAL_B_UP

GO Biological Process (1): system process (GO:0003008)

GO Molecular Function (3): GTPase activator activity (GO:0005096), calcium ion binding (GO:0005509), protein binding (GO:0005515)

GO Cellular Component (0):

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
multicellular organismal process	1
GTPase activity	1
enzyme activator activity	1
GTPase regulator activity	1
metal ion binding	1
binding	1

Protein interactions and networks

STRING

926 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
TBC1D9	RAB5A	P20339	688
TBC1D9	ELMOD2	Q8IZ81	559
TBC1D9	CALCOCO2	Q13137	514
TBC1D9	ESR1	P03372	501
TBC1D9	UBASH3B	Q8TF42	455
TBC1D9	RNF150	Q9ULK6	444
TBC1D9	TBC1D21	Q8IYX1	440
TBC1D9	KCNAB3	O43448	431
TBC1D9	KCNH3	Q9ULD8	427
TBC1D9	SGSM1	Q2NKQ1	424
TBC1D9	TBC1D17	Q9HA65	423
TBC1D9	GAD1	Q99259	417
TBC1D9	ATP6V1G2	O95670	413
TBC1D9	ARPP21	Q9UBL0	410
TBC1D9	ITPKA	P23677	409
TBC1D9	BAIAP2	Q9UQB8	409

IntAct

30 interactions, top by confidence:

A	B	Type	Score
TBC1D9	ABHD16A	psi-mi:“MI:0914”(association)	0.640
EPHA1	EXOC5	psi-mi:“MI:0914”(association)	0.530
TBC1D9	MYCBP2	psi-mi:“MI:0915”(physical association)	0.370
TBC1D9	SRSF2	psi-mi:“MI:0914”(association)	0.350
ADAM10	TSPAN9	psi-mi:“MI:0914”(association)	0.350
LANCL1	MYO7A	psi-mi:“MI:0914”(association)	0.350
	EXOC5	psi-mi:“MI:0914”(association)	0.350
YWHAG	HNRNPD	psi-mi:“MI:0914”(association)	0.350
HIDE1	TMEM120B	psi-mi:“MI:0914”(association)	0.350
LRRC25	POTEF	psi-mi:“MI:0914”(association)	0.350
EFNB1	KRBA1	psi-mi:“MI:0914”(association)	0.350
FAXC	METTL15	psi-mi:“MI:0914”(association)	0.350
KIR2DL4	GPR89A	psi-mi:“MI:0914”(association)	0.350
C3orf18	EXOC5	psi-mi:“MI:0914”(association)	0.350
ARL8A	DNAJC13	psi-mi:“MI:0914”(association)	0.350
CTAG2	PCNT	psi-mi:“MI:0914”(association)	0.350
SUN3	GAS6	psi-mi:“MI:0914”(association)	0.350
TBC1D9	SH3PXD2B	psi-mi:“MI:0914”(association)	0.350
BTNL9	TNPO2	psi-mi:“MI:0914”(association)	0.350
CTAG2	ASMTL	psi-mi:“MI:0914”(association)	0.350
FPR1	NBAS	psi-mi:“MI:0914”(association)	0.350
FZD10	PDE2A	psi-mi:“MI:0914”(association)	0.350
SRPRB	GSDME	psi-mi:“MI:0914”(association)	0.350
TBC1D9	ILVBL	psi-mi:“MI:0914”(association)	0.350
MAP1LC3C	BLTP3B	psi-mi:“MI:2364”(proximity)	0.270

BioGRID (73): TBC1D9 (Affinity Capture-MS), PRICKLE3 (Affinity Capture-MS), SRSF2 (Affinity Capture-MS), SNRPE (Affinity Capture-MS), SSB (Affinity Capture-MS), YME1L1 (Affinity Capture-MS), DDX41 (Affinity Capture-MS), PRPF38B (Affinity Capture-MS), ABHD16A (Affinity Capture-MS), TBC1D9B (Affinity Capture-MS), TMEM55A (Affinity Capture-MS), TBC1D9 (Affinity Capture-MS), MRS2 (Affinity Capture-MS), CPT1A (Affinity Capture-MS), TBC1D9 (Affinity Capture-MS)

ESM2 similar proteins: A0A0B7P9G0, A0A131MCZ8, A2PYH4, A3QM97, B4JXX2, B4QZU1, E1BPX4, G5EBX9, O00835, O13768, O14072, O74431, P32639, P36583, P36775, P38329, P39986, P40527, P47047, P53273, P53914, P87115, P91119, P92006, Q07093, Q09769, Q12296, Q21029, Q3UYK3, Q55EJ3, Q67XQ0, Q6BMW3, Q6CNR9, Q6FPE6, Q6P4Q7, Q6ZT07, Q84K47, Q8RY60, Q9BMK9, Q9FKF2

Diamond homologs: A0A087WVF3, A0A087WXS9, A0A087X179, A0A087X1G2, A2AWA9, A3KGB4, A6H6A9, A6NDS4, A6NER0, A6QP29, B0R0W9, B7ZAP0, B9A6J9, H2KZZ6, O60343, O60447, O95759, O97790, P0C7X1, P35125, P58802, P97366, Q0IIM8, Q10496, Q12317, Q12344, Q28CB1, Q3UYK3, Q4KMP7, Q5R372, Q5RAN1, Q5RCW6, Q5SVR0, Q5TC63, Q5ZJ17, Q60949, Q66K14, Q6DHY5, Q6IPX1, Q6ZT07

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

151 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	123
Likely benign	4
Benign	2

Top pathogenic / likely-pathogenic (0)

SpliceAI

3866 predictions. Top by Δscore:

Variant	Effect	Δscore
4:140622913:TGCCC:T	acceptor_gain	1.0000
4:140622914:GCCC:G	acceptor_gain	1.0000
4:140622915:CCC:C	acceptor_gain	1.0000
4:140622915:CCCC:C	acceptor_gain	1.0000
4:140622916:CC:C	acceptor_gain	1.0000
4:140622916:CCC:C	acceptor_gain	1.0000
4:140622917:CC:C	acceptor_gain	1.0000
4:140622918:C:CC	acceptor_gain	1.0000
4:140624215:CTTCC:C	acceptor_gain	1.0000
4:140624218:CC:C	acceptor_gain	1.0000
4:140624218:CCCT:C	acceptor_loss	1.0000
4:140624219:CC:C	acceptor_gain	1.0000
4:140624219:CCTA:C	acceptor_loss	1.0000
4:140624220:CTAC:C	acceptor_loss	1.0000
4:140624221:T:A	acceptor_loss	1.0000
4:140624308:CCTTA:C	donor_loss	1.0000
4:140624309:CTTAC:C	donor_loss	1.0000
4:140624312:A:AC	donor_gain	1.0000
4:140624313:C:CC	donor_gain	1.0000
4:140624313:C:G	donor_loss	1.0000
4:140624386:CAA:C	acceptor_gain	1.0000
4:140624389:C:CA	acceptor_loss	1.0000
4:140624389:C:CC	acceptor_gain	1.0000
4:140624393:C:CT	acceptor_gain	1.0000
4:140624393:C:T	acceptor_gain	1.0000
4:140624394:A:T	acceptor_gain	1.0000
4:140624399:A:AC	acceptor_gain	1.0000
4:140624399:A:C	acceptor_gain	1.0000
4:140624402:G:C	acceptor_gain	1.0000
4:140624402:G:GC	acceptor_gain	1.0000

AlphaMissense

8390 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
4:140622369:C:A	W1209C	1.000
4:140622369:C:G	W1209C	1.000
4:140622371:A:G	W1209R	1.000
4:140622371:A:T	W1209R	1.000
4:140622814:A:G	L1061P	1.000
4:140622814:A:T	L1061Q	1.000
4:140622817:A:G	L1060P	1.000
4:140622820:A:G	L1059P	1.000
4:140622901:A:G	L1032P	1.000
4:140622910:A:G	F1029S	1.000
4:140639111:A:G	L827P	1.000
4:140639150:C:G	R814P	1.000
4:140657572:A:G	L721P	1.000
4:140657682:A:C	S684R	1.000
4:140657682:A:T	S684R	1.000
4:140657684:T:G	S684R	1.000
4:140657698:A:G	L679P	1.000
4:140657705:A:G	W677R	1.000
4:140657705:A:T	W677R	1.000
4:140657779:A:G	L652P	1.000
4:140657800:T:A	D645V	1.000
4:140657801:C:G	D645H	1.000
4:140657812:C:T	G641D	1.000
4:140659588:C:G	G641R	1.000
4:140659641:A:G	L623P	1.000
4:140659648:A:G	W621R	1.000
4:140659648:A:T	W621R	1.000
4:140659649:G:C	F620L	1.000
4:140659649:G:T	F620L	1.000
4:140659651:A:G	F620L	1.000

dbSNP variants (sampled 300 via entrez): RS1000029678 (4:140738343 T>A,G), RS1000032364 (4:140659502 C>T), RS1000046398 (4:140744843 A>G), RS1000073777 (4:140648882 G>A), RS10001070 (4:140726106 T>C), RS10001181 (4:140672198 A>G), RS1000131817 (4:140700239 C>T), RS1000170426 (4:140721050 C>T), RS1000182220 (4:140643477 C>T), RS1000214283 (4:140731666 C>T), RS10002459 (4:140633795 G>A,T), RS1000260693 (4:140681108 T>G), RS1000261396 (4:140643552 T>A,C), RS1000277233 (4:140638421 C>A,G), RS1000312199 (4:140661116 G>A,C)

Disease associations

OMIM: gene MIM:618035 | disease phenotypes:

GenCC curated gene-disease

Mondo (1): attention deficit-hyperactivity disorder (MONDO:0007743)

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

5 associations (top):

Study	Trait	p-value
GCST010725_4	Malaria	4.000000e-10
GCST010725_84	Malaria	7.000000e-11
GCST010725_89	Malaria	7.000000e-11
GCST011957_28	Prostate cancer	2.000000e-08
GCST012052_6	Waist circumference	8.000000e-07

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

34 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
trichostatin A	affects cotreatment, decreases expression	3
sodium arsenite	decreases expression, increases expression	2
entinostat	decreases expression, affects cotreatment	2
Estradiol	affects cotreatment, increases expression, decreases expression	2
Cyclosporine	decreases expression	2
bisphenol F	increases expression, affects cotreatment	1
triphenyl phosphate	affects expression	1
tris(1,3-dichloro-2-propyl)phosphate	decreases expression	1
potassium chromate(VI)	decreases expression	1
testosterone-3-carboxymethyloxime-bovine serum albumin conjugate	affects expression	1
CGP 52608	affects binding, increases reaction	1
2-palmitoylglycerol	increases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression	1
abrine	increases expression	1
dorsomorphin	affects cotreatment, decreases expression	1
bisphenol S	affects cotreatment, increases expression	1
Bortezomib	increases expression	1
Leflunomide	increases expression	1
Acetaminophen	decreases expression	1
Air Pollutants	decreases expression, increases abundance	1
Dexamethasone	affects cotreatment, increases expression	1
Doxorubicin	decreases expression	1
Indomethacin	affects cotreatment, increases expression	1
Lead	affects expression	1
Pesticides	increases methylation	1
Quercetin	decreases expression	1
Tetrachlorodibenzodioxin	affects cotreatment, increases expression, decreases expression	1
Tretinoin	increases expression	1
Valproic Acid	affects expression	1
1-Methyl-3-isobutylxanthine	increases expression, affects cotreatment	1

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00152750	PHASE4	UNKNOWN	Study of Clonidine on Sleep Architecture in Children With Tourette’s Syndrome (TS) and Comorbid ADHD
NCT00181571	PHASE4	COMPLETED	A Double-Blind Comparison of Concerta and Placebo in Adults With Attention Deficit Hyperactivity Disorder
NCT00181675	PHASE4	COMPLETED	A Double-Blind Comparison of Galantamine HBr and Placebo in Adults With Attention Deficit Hyperactivity Disorder
NCT00181714	PHASE4	COMPLETED	Prevention of Cigarette Smoking in Attention Deficit Hyperactivity Disorder (ADHD) Youth With Concerta
NCT00181948	PHASE4	COMPLETED	Strattera Treatment in Children With ADHD Who Have Poor Response to Stimulant Therapy
NCT00181987	PHASE4	COMPLETED	Concerta in the Treatment of ADHD in Youth and Adults With Bipolar Disorder
NCT00190736	PHASE4	COMPLETED	Efficacy and Safety of Once-Daily Atomoxetine Hydrochloride in Adults With ADHD Over an Extended Period of Time (6 Months)
NCT00190775	PHASE4	COMPLETED	A Randomized, Double-Blind Comparison of Placebo and Atomoxetine Hydrochloride Given Once a Day in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
NCT00190879	PHASE4	COMPLETED	Placebo-Controlled Study of Atomoxetine Hydrochloride in the Treatment of Adults With ADHD and Comorbid Social Anxiety Disorder
NCT00190957	PHASE4	COMPLETED	Atomoxetine Treatment of Adults With ADHD and Comorbid Alcohol Abuse
NCT00191035	PHASE4	COMPLETED	Maintenance of Benefit With Atomoxetine Hydrochloride in Adolescents With ADHD
NCT00191048	PHASE4	COMPLETED	Treatment With Atomoxetine Hydrochloride in Children and Adolescents With ADHD
NCT00191633	PHASE4	COMPLETED	Study of Atomoxetine in Children With ADHD to Assess Symptomatic and Functional Outcomes
NCT00191906	PHASE4	COMPLETED	Comparison of Atomoxetine and Placebo in Children With Attention-Deficit/Hyperactivity Disorder (ADHD) and/or Reading Disorder (RD)
NCT00216918	PHASE4	COMPLETED	Neuropsychological Functioning in Children With Attention-Deficit/Hyperactivity Disorder.
NCT00221962	PHASE4	COMPLETED	Study of Aripiprazole (Abilify) in Children With ADHD (Attention Deficit Hyperactivity Disorder)
NCT00223561	PHASE4	COMPLETED	Methylphenidate and Driving Ability in Adult Patients With Attention-Deficit Hyperactivity Disorder
NCT00299234	PHASE4	TERMINATED	Atomoxetine for Children With Acquired Attentional Disorders Following Completion of Chemotherapy for ALL
NCT00302406	PHASE4	COMPLETED	Naturalistic Substitution of Concerta in Adult Subject With ADHD Receiving Immediate Release Methylphenidate
NCT00305370	PHASE4	COMPLETED	Aripiprazole Associated With Methylphenidate in Children and Adolescents With Bipolar Disorder and ADHD
NCT00381758	PHASE4	COMPLETED	The COMACS Study: A Comparison of Methylphenidates in an Analog Classroom Setting
NCT00406354	PHASE4	COMPLETED	Comparison of Atomoxetine Versus Placebo in Children and Adolescents With ADHD and Comorbid ODD in Germany
NCT00434213	PHASE4	COMPLETED	Characterization of Dermal Reactions in Pediatric Patients With ADHD Using DAYTRANA
NCT00468143	PHASE4	COMPLETED	A Within-Subject Cross-Over Comparison Between Immediate Release and Extended Release Adderall
NCT00471354	PHASE4	COMPLETED	A Study for Patients With Attention-Deficit/Hyperactivity Disorder Treated With Atomoxetine
NCT00483106	PHASE4	COMPLETED	Clinical and Pharmacogenetic Study of Attention Deficit With Hyperactivity Disorder (ADHD)
NCT00485849	PHASE4	COMPLETED	A Study of Atomoxetine for Attention Deficit and Hyperactive/Impulsive Behaviour Problems in Children With ASD
NCT00485875	PHASE4	COMPLETED	Safety and Efficacy of Switching From a Stimulant Medication to Atomoxetine in Children and Adolescents With ADHD
NCT00486122	PHASE4	COMPLETED	Evaluation of Continuous Symptom Treatment of ADHD
NCT00500071	PHASE4	COMPLETED	Dose-Optimization Study Evaluating the Efficacy, Safety and Tolerability of Vyvanse (Lisdexamfetamine Dimesylate) in Children Aged 6-12 Diagnosed With ADHD
NCT00506727	PHASE4	COMPLETED	Analog Classroom Study Comparison of ADDERALL XR With STRATTERA in Children Aged 6-12 With ADHD
NCT00510276	PHASE4	COMPLETED	Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) With Atomoxetine in Young Adults and Its Effects on Functional Outcomes
NCT00517504	PHASE4	COMPLETED	Methylphenidate Study in Young Children With Developmental Disorders
NCT00517647	PHASE4	COMPLETED	Atomoxetine Pilot Study in Preschool Children With ADHD
NCT00518232	PHASE4	COMPLETED	A Study to Determine Effective and Tolerable Titration Scheme for OROS-Methylphenidate in Children With Attention-deficit Hyperactivity Disorder
NCT00530257	PHASE4	COMPLETED	Study of the Effects of Osmotic-Release Oral System (OROS) Methylphenidate (Concerta) on Attention and Memory
NCT00536419	PHASE4	UNKNOWN	Impact of Attention Deficit/Hyperactivity Disorder and Substance Use Disorder on Motorcycle Traffic Accidents
NCT00546910	PHASE4	COMPLETED	Comparison of Atomoxetine Versus Placebo in Children With Attention-Deficit/Hyperactivity Disorder (ADHD)
NCT00552266	PHASE4	UNKNOWN	Methylphenidate in ADHD With Trichotillomania
NCT00564954	PHASE4	COMPLETED	A Study of Dex-methylphenidate Extended Release in Children (6-12 Years) With Attention-Deficit/Hyperactivity Disorder (ADHD)